We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
High Dose Lamivudine in HBV-Related Cirrhotic Patients with Unsatisfactory Response After Adefovir Add-On.
- Authors
Montagnani, Marco; Giandinoto, Marina; Lisotti, Andrea; Galli, Silvia; Azzaroli, Francesco; Buonfiglioli, Federica; Turco, Laura; Aldini, Rita; Mazzella, Giuseppe
- Abstract
Background: Before tenofovir approval for chronic hepatitis B therapy, the clinical management of patients with suboptimal response or virological breakthrough during combination treatment with lamivudine and adefovir dipivoxil was a difficult clinical challenge. Aims: In order to improve virologic response and reduce the risk of decompensation, we evaluate the efficacy of a high dose of lamivudine on chronic HBV patients who have previously presented an unsatisfactory response during treatment with lamivudine 100mg/day and adefovir 10mg/day. Methods: Six patients with HBV-related liver cirrhosis were prospectively enrolled. All were HBeAg-negative and presented a suboptimal response or virological breakthrough after "adefovir add-on" because of development of clinical breakthrough during Lamivudine treatment. Lamivudine dose was increased to 200 or 300mg, depending on viral load. After 12 months of follow-up, virological and biochemical response were evaluated. Results: After 12 months of high-dose lamivudine, all patients (6/6, 100%) achieved a significant decrease of serum HBV DNA (mean reduction 2,62 ± 1,15 Log10 UI/ml, P = 0.03) and normalized ALT. In three patients (3/6, 50%), HBV DNA became undetectable within 6 months. No patient developed liver decompensation and no significant changes occurred in serum creatinine, serum and urinary electrolytes. No adverse events were registered. Conclusions: In our experience, rescue strategy with high-dose lamivudine inhibited viral replication leading to undetectability of serum HBVDNA. This rescue treatment presented a good safety profile, without adverse events during the study period. Customized increase of nucleos(t)ide analogues dose in difficult-to-treat patients may be a proficient approach in challenging clinical setting.
- Subjects
LAMIVUDINE; HEPATITIS B; DRUG efficacy; CIRRHOSIS of the liver; VIRAL load; SERUM; FOLLOW-up studies (Medicine)
- Publication
Digestive Diseases & Sciences, 2012, Vol 57, Issue 2, p561
- ISSN
0163-2116
- Publication type
Article
- DOI
10.1007/s10620-011-1873-x